UK markets open in 7 hours 8 minutes

Benitec Biopharma Limited (BNTC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
8.45+1.00 (+13.42%)
At close: 04:00PM EDT
8.40 -0.05 (-0.59%)
After hours: 07:22PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close7.45
Open7.56
Bid5.89 x 200
Ask9.92 x 200
Day's range7.52 - 8.50
52-week range1.86 - 9.01
Volume84,658
Avg. volume83,203
Market cap70.486M
Beta (5Y monthly)1.02
PE ratio (TTM)N/A
EPS (TTM)-236.13
Earnings date13 May 2024 - 17 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est16.00
  • GlobeNewswire

    Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study

    -First efficacy signals demonstrated for a gene therapy under development for Oculopharyngeal Muscular Dystrophy (OPMD) which affects ~15,000 patients worldwide- - BB-301 facilitated improvements across multiple measures of swallowing function in the first Phase 1b/2a clinical study subject as compared to pretreatment assessments conducted during the observational natural history portion of the study- -Virtual R&D Day being held today at 9:00 am EDT, details below- HAYWARD, Calif., April 18, 202

  • GlobeNewswire

    Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million

    HAYWARD, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced a $40.0 million private investment in public equity (PIPE) financing from the sale of 5,749,152 shares of its common stock at a price per share of $4.80, and, in lieu of

  • GlobeNewswire

    Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024

    HAYWARD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced it will host a virtual R&D Day, on Thursday, April 18, 2024 from 9:00 AM to 11:00 AM ET. To register, click here. The event will feature two key opinion leaders who will dis